Target intelligence / Profile preview

Sigma-1 receptor and Sigma-2 receptor (S1R/S2R)

Target
S1R/S2R
Molecular classification
Receptor, Chaperone, Transmembrane protein
01

Overview

The Sigma-1 and Sigma-2 receptors are distinct, non-opioid intracellular proteins that serve as key regulators of cellular proteostasis and lipid metabolism. The Sigma-1 receptor (S1R) functions as a ligand-operated molecular chaperone at the mitochondria-associated endoplasmic reticulum membrane (MAM), where it modulates calcium signaling via the IP3 receptor and protects against ER stress (UniProt Q99720). The Sigma-2 receptor (S2R), recently identified as Transmembrane Protein 97 (TMEM97), is involved in cholesterol homeostasis, lysosomal function, and the regulation of cell proliferation (UniProt Q5BJF2; Alon et al., 2017, PMID: 28559487). Both receptors are widely expressed in the brain and peripheral tissues, and their dysregulation is linked to neurodegenerative diseases, psychiatric conditions, and various cancers (Su et al., 2010, PMID: 20638385). Therapeutic strategies targeting S1R often focus on neuroprotection and cognitive enhancement, while S2R ligands are being investigated for their potential in oncology and the treatment of neuropathic pain.

Other names
Sigma-1 receptorSigma-2 receptorSIGMAR1TMEM97Sigma non-opioid intracellular receptor 1Transmembrane protein 97MAC30SR-BPSR31747
02

Mechanism of action

Sigma-1 receptor ligands act as molecular chaperone modulators at the mitochondria-associated ER membrane to regulate calcium signaling and protein folding. Sigma-2 receptor ligands modulate cholesterol trafficking and lysosomal integrity, influencing cell survival and neuroplasticity.

03

Biological functions

Calcium signalingProtein foldingCholesterol homeostasisER stress responseNeuroprotectionApoptosisLipid metabolism
04

Disease associations

Alzheimer's diseaseParkinson's diseaseAmyotrophic lateral sclerosisCancerNeuropathic painDepressionSchizophrenia
05

Safety considerations

Off-target binding to opioid and dopamine receptorsCNS side effects such as sedation or dizzinessPotential for QT interval prolongation
06

Interacting drugs

Fluvoxamine

9 more in the full profile.

07

Biomarkers

[18F]FTC-146[18F]ISO-1[11C]SA4503

Beyond the preview

Go deeper on Sigma-1 receptor and Sigma-2 receptor (S1R/S2R).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sigma-1 receptor and Sigma-2 receptor (S1R/S2R).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call